PMLiVE4d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on ...
PMLiVE6d
How women are revolutionising rare disease
Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges ...
PMLiVE6d
British Skin Foundation receives £10,000 donation from Circle Health Group
The British Skin Foundation’s (BSF) skin research programme has received a £10,000 donation from Circle Health Group (CHG) ...
PMLiVE4d
J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study
Johnson & Johnson (J&J) and Legend Biotech have shared positive long-term results for their BCMA-directed T-cell ...
PMLiVE5d
‘Causes That Count, Health’ report – key issues affecting global health
Public health, access to healthcare services, and food and nutrition are some of the most important issues facing people ...
PMLiVE6d
Gaps in obesity care and education
Yesterday marked World Heart Day, and Medscape is at the forefront with a featured article in Media Planet's cardiology ...
PMLiVE5d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission ...
PMLiVE4d
FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients
The US Food and Drug Administration (FDA) has approved IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms ...
PMLiVE5d
Successful Education at ESC
Medscape wants to take the opportunity to look back and recap what was accomplished at ESC 2024. At this year’s event, ...
PMLiVE6d
Ipsen’s Kayfanda granted EC approval to treat cholestatic pruritus in Alagille syndrome
Ipsen’s Kayfanda (odevixibat) has been approved by the European Commission (EC) under exceptional circumstances to treat ...
PMLiVE4d
Eli Lilly announces new $4.5bn US site for manufacturing and drug development
Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ...